Volume 78, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


To study outcome determinants of schistosomal periportal thickening/fibrosis (PPT/F), 199 subjects (mean age = 24.0 years, range = 7–68 years), 109 with mild (image pattern C) PPT/F, 69 with moderate (image pattern D) PPT/F, and 21 with severe (image patterns E and F) PPT/F were treated with praziquantel and evaluated every six months for a mean duration of 26 months. Subjects excreting eggs during any of the six-month evaluations were offered repeat treatment. Thirty-five had some improvement, and 69 had total resolution of PPT/F, of which 63.8% resolved within one year. Compared with subjects with moderate lesions, a significantly higher proportion of subjects with mild lesions had resolution/improvement of PPT/F (40.6% versus 69.7%, < 0.001). Subjects with severe PPT/F showed no improvement. Resolution of PPT/F was significantly more frequent at a younger age, among seronegative for hepatitis B virus and among those with a lower frequency of post-treatment recurrence of infections.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Friedman SL, 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to injury. J Biol Chem 75 : 2247–2250. [Google Scholar]
  2. Gressner AM, 1995. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 22 (Suppl 2): 28–36. [Google Scholar]
  3. Andrade ZA, Guerret S, Fernandes ALM, 1999. Myofibroblasts in schistosomal portal fibrosis of man. Mem Inst Oswaldo Cruz 94 : 87–93. [Google Scholar]
  4. Andrade ZA, 2004. Schistosomal hepathopathy. Mem Inst Oswaldo Cruz 99 (Suppl): 51–57. [Google Scholar]
  5. Fallon PG, Cooper RO, Probert AJ, Doenhoff MJ, 1992. Immune-dependent chemotherapy of schistosomiasis. Parasitology 105 (Suppl): S41–S48. [Google Scholar]
  6. Brindley PJ, Sher A, 1987. The chemotherapeutic efficacy of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 139 : 215–220. [Google Scholar]
  7. Mutapi F, Ndhlovu PD, Hagan P, Spicer JT, Mduluza T, Turner CM, Chandiwana SK, Woollhouse MEJ, 1998. Chemotherapy accelerates the development of acquired immune response to Schistosoma haematobium infection. J Infect Dis 178 : 289–293. [Google Scholar]
  8. Hirose Y, Kirinoki M, Matsuda H, 2003. Efficacy of administration of praziquantel on 2 days 2 weeks apart against Schistosoma japonicum eggs in mice. Parasitol Int 52 : 141–146. [Google Scholar]
  9. Giboda M, Smith JM, 1994. Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice. J Trop Med Hyg 97 : 98–102. [Google Scholar]
  10. Homeida M, Abdel-Gadir AF, Cheever AW, Bennett JL, Arbab BM, Ibrahium SZ, Abdel-Salam IM, Dafalla AA, Nash TE, 1988. Diagnosis of pathologically confirmed Symmers periportal fibrosis by ultrasonography: a prospective blinded study. Am J Trop Med Hyg 38 : 86–91. [Google Scholar]
  11. Abdel-Wahab MF, Esmat G, Milad M, Abdel-Razek S, Strickland GT, 1989. Characteristic sonographic pattern of schistosomal hepatic fibrosis. Am J Trop Med Hyg 40 : 72–76. [Google Scholar]
  12. Homeida MA, Fenwick A, Dafalla AA, Suliman S, Kardaman MW, el Tom I, Nash T, Bennett JL, 1988. Effect of anti-schistosomal chemotherapy on prevalence of Symmer’s periportal fibrosis in Sudanese villages. Lancet II : 437–440. [Google Scholar]
  13. Homeida MA, El-Tom I, Nash T, Bennett JL, 1991. Association of the therapeutic activity of praziquantel with the reversal of Symmers’ fibrosis induced by Schistosoma mansoni. Am J Trop Med Hyg 45 : 360–365. [Google Scholar]
  14. Homeida MM, Eltoum IA, Ali MM, Suliaman SM, Elobied EA, Mansour M, Saad AM, Bennett JL, 1996. The effectiveness of annual vs. biennial mass chemotherapy in reducing morbidity due to schistosmiasis: a prospective study in Gezira-Managil, Sudan. Am J Trop Med Hyg 54 : 140–145. [Google Scholar]
  15. Mohamed-Ali Q, Doehring-Schwerdtfeger E, Abdel-Rahim IM, Schlake J, Kardorff R, Franke D, Kaiser C, Elsheikh M, Abdalla M, Schafer P, 1991. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. Am J Trop Med Hyg 44 : 444–451. [Google Scholar]
  16. Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kardorff R, Kaiser C, Franke D, Schlake J, Richter J, Elsheikh M, Mohamed-Ali Q, Ehrich JH, 1992. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Am J Trop Med Hyg 46 : 409–415. [Google Scholar]
  17. Boisier P, Ramarokoto CE, Ravaoalimalala VE, Rabarijaona L, Serieye J, Roux J, Esterre P, 1998. Reversibility of Schistosoma mansoni-associated morbidity after yearly mass praziquantel therapy: ultrasonographic assessment. Trans R Soc Trop Med Hyg 92 : 451–453. [Google Scholar]
  18. Frenzel K, Grigull L, Odongo-Aginya E, Ndugwa CM, Loroni-Lakwo T, Schweigmann U, Vester U, Spannbrucker N, Doehring E, 1999. Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda. Am J Trop Med Hyg 60 : 927–931. [Google Scholar]
  19. World Health Organization, 2000. Richter J, Hatz C, Campagne G, Bergquist NR, Jenkins JM, eds. Ultrasound in Schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of Schistosomiasis-Related Morbidity. Geneva: World Health Organization. TDR/STR/SCH/00.1.TDR/WHO. Accessed June 15, 2007. Available from http://www.who.int/tdr/publications/publications/pdf/ultrasound.pdf.
  20. Berhe N, Geitung JT, Medhin G, Gundersen SG, 2006. Large scale evaluation of WHO’s ultrasonographic staging system of schistosomal periportal fibrosis in Ethiopia. Trop Med Int Health 11 : 1286–1294. [Google Scholar]
  21. Birrie H, Abebe F, Gundersen SG, Medhin G, Berhe N, Gemetchu T, 1998. Epidemiology of schistosomiasis mansoni in three endemic communities in north-east Ethiopia: baseline characteristics before endod based intervention. Ethiop Med J 36 : 101–111. [Google Scholar]
  22. Peters PA, El Alamy M, Warren KS, Mahmoud AA, 1980. Quick Kato smear for field quantitation of Schistosoma mansoni eggs. Am J Trop Med Hyg 29 : 217–219. [Google Scholar]
  23. Berhe N, Medhin G, Erko B, Smith T, Gedamu S, Bereded D, Moore R, Habte E, Redda A, Gebre-Michael T, Gundersen SG, 2004. Variations in helminth faecal egg counts in Kato-Katz thick smears and their implications in assessing infection status with Schistosoma mansoni. Acta Trop 92 : 205–212. [Google Scholar]
  24. Engels D, Sinzinkayo E, Gryseels B, 1996. Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications. Am J Trop Med Hyg 54 : 319–324. [Google Scholar]
  25. Engels D, Sinzinkayo E, de Vlas SJ, Gryseels B, 1997. Intra-specimen fecal egg count variation in Schistosoma mansoni infection. Am J Trop Med Hyg 57 : 571–577. [Google Scholar]
  26. Utzinger J, Booth M, N’Goran EK, Muller I, Tanner M, Lengeler C, 2001. Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology 122 : 537–544. [Google Scholar]
  27. De Jesus AR, Miranda DG, Miranda RG, Araujo I, Magalhaes A, Bacellar M, Carvalho EM, 2000. Morbidity associated with Schistosoma mansoni infection determined by ultrasound in an endemic area of Brazil, Caatinga do Moura. Am J Trop Med Hyg 63 : 1–4. [Google Scholar]
  28. Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, Gemetchu T, 1999. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 72 : 53–63. [Google Scholar]
  29. Berhe N, Myrvang B, Gundersen SG, 2007. Intensity of Schistosoma mansoni infection, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis: a large-scale, community-based morbidity study in Ethiopia. Am J Trop. Med Hyg 77 : 1079–1086. [Google Scholar]
  30. Kabatereine NB, Kemijumbi J, Ouma JH, Sturrock RF, Butterworth AE, Madsen H, Ørnbjerg N, Dunne DW, Vennervald BJ, 2003. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus of Lake Albert, Uganda. Trans R Soc Trop Med Hyg 97 : 599–603. [Google Scholar]
  31. Tchuem-Tchuente LA, Southgate VR, Mbaye A, Engels D, Gryseels B, 2001. The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal. Trans R Soc Trop Med Hyg 95 : 65–66. [Google Scholar]
  32. Pica-Mattoccia L, Cioli D, 2004. Sex and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parastol 34 : 527–533. [Google Scholar]
  33. Xiao SH, Catto BA, Webster LT, 1985. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 151 : 1130–1137. [Google Scholar]
  34. Ghaffar YA, Fattah SA, Kamel M, Badr RM, Mahomed FF, Strickland GT, 1991. The impact of endemic schistosomiasis on acute viral hepatitis. Am J Trop Med Hyg 45 : 743–750. [Google Scholar]
  35. Mohamed A, Elisheikh A, Ghandour Z, Al-Karawi M, 1998. Impact of hepatitis C virus infection on schistosomal liver disease. Hepatogastroenterology 45 : 1492–1496. [Google Scholar]
  36. Badawi AF, Michael MS, 1999. Risk factors for hepatocellular carcinoma in Egypt: the role of hepatitis B viral infection and schistosomias. Anticancer Res 19 : 4565–4569. [Google Scholar]
  37. Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, Rasenack JW, 2000. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 20 : 281–289. [Google Scholar]
  38. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I, 2000. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 : 887–891. [Google Scholar]
  39. Tsega E, Mengesha B, Hansson BG, Lindberg J, Nordenfelt E, 1986. Hepatitis, A, B, and delta infection in Ethiopia: a serological survey with demographic data. Am J Epidemiol 123 : 344–350. [Google Scholar]
  40. Kefene H, Rapicetta M, Rossi GB, Bisanti L, Bekura D, Morace G, Palladine P, Di Rienza A, Conti S, Bassani F, 1988. Ethiopian National Hepatitis B Study. J Med Virol 24 : 75–84. [Google Scholar]
  41. Abebe A, Nokes DJ, Dejene A, Enquselassie F, Messele T, Cutts FT, 2003. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. Epidemiol Infect 131 : 757–770. [Google Scholar]
  42. World Health Organization, 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser 912 : 1–57. [Google Scholar]

Data & Media loading...

  • Received : 19 Aug 2007
  • Accepted : 07 Nov 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error